Handelsavisen
prelaunch
Companies Healthcare HCT.AX
HC
HCT.AX ASX Biotechnology & Medical Research

Holista CollTech Ltd

A$0,07
Open in Charts → Attach watcher ⌖
AUD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
ROE
Net margin
Debt / equity
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Holista CollTech Ltd is a biotechnology company focused on the development and commercialization of collagen-based products for healthcare diagnostics and other applications.

Business. Holista CollTech Ltd (HCT.AX) is a healthcare diagnostics company operating within the biotechnology and medical research industry. The firm is headquartered in Australia and is primarily listed on the Australian Securities Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityHealthcare Diagnostics
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
not yet wired
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning HCT.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to HCT.AX. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Holista CollTech Ltd (HCT.AX) is a healthcare diagnostics company operating within the biotechnology and medical research industry. The firm is headquartered in Australia and is primarily listed on the Australian Securities Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryBiotechnology & Medical Research
    ActivityHealthcare Diagnostics
    AI synthesis
    GENERATED

    Holista CollTech operates with a capital structure that includes 367,834,364 basic and diluted shares outstanding, indicating no immediate dilution pressure from share issuance. The company's liquidity position could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents, suggesting a lack of transparency in its short-term financial health.

    The company reported a revenue of 38,000 AUD and an EPS of -0.10 AUD, indicating a loss per share and a very low revenue base. These figures suggest that the company is not yet profitable and is likely in an early-stage or development phase, which is common in the biotechnology and medical research industry.

    Holista CollTech's revenue is not segmented by geographic region or business segment in the available data, making it difficult to assess the geographic or product concentration of its revenue. This lack of segmentation could pose a risk if the company is overly reliant on a single market or product line.

    The company's growth trajectory is not clearly defined in the available data, as there are no forward-looking revenue projections or historical growth rates provided. The absence of detailed growth metrics makes it challenging to assess the company's potential for future expansion or profitability.

    The risk assessment indicates a low dilution risk, but the company's liquidity risk could not be evaluated due to insufficient financial data. This lack of information may hinder investors' ability to fully understand the company's financial stability and operational risks.

    There are no recent events or filings mentioned in the available data that would provide insight into the company's current operations or strategic direction. The absence of recent disclosures or transcripts suggests a lack of public communication or transparency from the company.

    Key takeaways
    • Holista CollTech is a biotechnology company with a focus on collagen-based products for healthcare diagnostics.
    • The company reported a revenue of 38,000 AUD and an EPS of -0.10 AUD, indicating a loss per share and a very low revenue base.
    • The company's liquidity position could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.
    • There is no segmentation of revenue by geographic region or business segment, making it difficult to assess the geographic or product concentration of its revenue.
    • The company's growth trajectory is not clearly defined in the available data, as there are no forward-looking revenue projections or historical growth rates provided.
    • The risk assessment indicates a low dilution risk, but the company's liquidity risk could not be evaluated due to insufficient financial data.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Annual
    ANNUALFiled 2008-09-19
    FY 2008 · Full-year highlights

    Revenue A$5.8M, +3,3% YoY; Operating income −365,1% YoY.

    RevenueA$5.8M+3,3 % YoY
    Operating income-A$815.8k−365,1 % YoY
    Net income-A$948.9k−1 026,8 % YoY
    Free cash flow-A$920.0k−24 303,7 % YoY
    EPS
    Operating cash flow-A$1.5M−50,5 % YoY
    Financials
    Income statement
    RevenueA$5.8M
    Gross profitA$3.0M
    Operating income-A$815.8k
    Net income-A$948.9k
    Margins
    Gross margin52.0%
    Operating margin-14.1%
    Net margin-16.4%
    FCF margin-15.9%
    Balance sheet
    Total assetsA$5.9M
    Total liabilitiesA$4.8M
    Total equityA$1.1M
    Cash & equivalentsA$2.2M
    Long-term debtA$1.6M
    Cash flow
    Operating cash flow-A$1.5M
    CapEx-A$23.4k
    Free cash flow-A$920.0k
    SBC
    P&L flow · revenue → net income
    Revenue A$5.8MOperating costs A$6.6MTax A$133.1kNet income A$948.9k
    Highlights
    • Revenue A$5.8M, +3,3% YoY
    • Operating income −365,1% YoY
    • Net income −1 026,8% YoY
    • Free cash flow −24 303,7% YoY
    • Net margin -16.4%

    Valuation FY

    Market price
    A$0,07
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    Net cash
    Current ratio
    Debt / equity
    ROA
    ROE
    Cash conversion
    CapEx / revenue
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskUnknown

    Benchmarks vs cohort

    No cohort benchmark data available for this issuer yet.

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    Source documents
    • Holista CollTech Ltd Market data — financials · 2026-05-28
    • Holista CollTech Ltd Market data — analyst estimates · 2026-05-28

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    HCT.AXCanonical
    ASX · AUD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskUnknown

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2008-09-19 12:12 UTCEARNINGSAnnual results — FY 2008 Revenue AUD 5.8M · Net AUD -0.9M
    2007-09-03 10:59 UTCEARNINGSAnnual results — FY 2007 Revenue AUD 5.6M · Net AUD -0.1M
    2006-10-31 11:18 UTCEARNINGSAnnual results — FY 2006 Revenue AUD 8.2M · Net AUD -1.5M
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage